The invention relates to a strain suitable for producing a live, orally applicable Escherichia coli vaccine for the prevention of post-weaning diarrhoea in pigs, and the procedure suitable for producing that strain. The essence of the strain is that the enterotoxin-free and originally wild-type Escherichia coli strain simultaneously produces two adhesive fimbriae (F4 and F18), whereas the essence of the procedure is that the enterotoxin-producing ability if the wild, pathogenic, enterotoxigenic Escherichia coli strain originally capable of producing enterotoxins and F18 fimbriae is abolished by a genetic intervention while retaining the ability of the strain to produce F18 fimbria facilitating adhesion to the small intestinal wall of weaned piglets, and subsequently the strain thus modified is rendered capable of producing a further surface adhesion fimbria (F4).

MTA Allatorvos-Tudomanyi K.I.

Escherichia coli strain for an oral vaccine against post-weaning diarrhea in pigs

GLP-2 analogues are disclosed which comprise one of more substitutions as compared to [hGly2]GLP-2 and which improved biological activity in vivo and/or improved chemical stability, e.g., as assessed in in vitro stability assays. More particularly, preferred GLP-2 analogues disclosed herein comprise substitutions at one or more of positions 8, 16, 24 and/or 28 of the wild-type GLP-2 sequence, optionally in combination with further substitutions at position 2 (as mentioned in the introduction) and one or more of positions 3, 5, 7, 10 and 11, and/or a deletion of one or more of amino acids 31 to 33 and/or the addition of a N-terminal or C-terminal stabilizing peptide sequence. The analogues are particularly useful for the prophylaxis or treatment of stomach and bowel-related disorders and for ameliorating side effects of chemotherapy. Also disclosed are methods and kits for selecting a patient from populations suited for treatment with GLP-2 analogues.

Zealand Pharma A/S

Methods of treating chemotherapy-induced diarrhea/mucositis using glucagon-like-peptide-2(GLP-2)analogues

The present invention relates to improved diagnostic methods and kits for differentiating between (a) animals administered a chimeric pestivirus, and (b) animals infected with a wild-type bovine viral diarrhea virus (BVDV) or immunized with a conventional BVDV vaccine.

Ankenbauer; Robert G.

Nelson; Lynn D.

Oien; Nancee L.

Welch; Siao-Kun W.

Zoetis Services LLC

Vaccine diagnostics

The present invention relates to chimeric pestiviruses having utility as immunogenic compositions and vaccines. Also described herein are methods and kits for treating or preventing the spread of bovine viral diarrhea virus infection, as well as methods and kits for differentiating between vaccinated and wild-type infected animals.

Luo; Yugang

Welch; Siao-Kun Wan

Yuan; Ying

Ankenbauer; Robert Gerard

Chimeric pestiviruses

A detoxified recombinant E. coli heat-labile enterotoxin mutant, LTS61K, is employed as a carrier protein to conjugate polysaccharide. The LTS61K contains a mutated mature sub-unit A (LTA) that includes lysine at amino acid position 61 and a wild-type mature sub-unit B (LTB). Various types of bacterial capsular polysaccharide antigens were chemically conjugated with the LTS61K protein by a reductive amination reaction. The conjugated polysaccharide-LTS61K products were physically, chemically and biochemically identified as soluble form. Rabbits were immunized intramuscularly to determine the immunogenicity of conjugated vaccines by ELISA to detect anti-polysaccharide antigen IgG titers and serum bactericidal assay thereby determining the functional activity of the antibodies. Study results show that conjugated polysaccharide-LTS61K vaccines induce higher polysaccharide-specific IgG titers and greater bactericidal activity in sera than that of polysaccharide alone or polysaccharide mixed with LTS61K. The presence of anti-LTS61K serum IgG antibody alleviates travel diarrhea caused by E. coli (ETEC enterotoxigenic E. coli).

Hsu; Yu-Shen

Kou; I-Ling

Hung; Kuo-Chan

Lu; Yuan-Hsin

Yuan; Ta-Tung

DEVELOPMENT CENTER FOR BIOTECHNOLOGY

Polysaccharide conjugation with detoxified E. coli heat labile enterotoxin (LT) used as vaccine

wild

diarrhea

wild/diarrhea

Escherichia coli strain for an oral vaccine against post-weaning diarrhea in pigs

Methods of treating chemotherapy-induced diarrhea/mucositis using glucagon-like-peptide-2(GLP-2)analogues

Vaccine diagnostics

Chimeric pestiviruses

Polysaccharide conjugation with detoxified E. coli heat labile enterotoxin (LT) used as vaccine

科学支持的最完整的草药数据库